High affinity monoclonal antibodies targeting glypican-2 and uses thereof

US12012463B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Mitchell Ho · Urbana, US
• Nan Li · Tianjin, CN
• Bryan D. Fleming · Bethesda, US

Key dates

• Filing date: Aug 6, 2019
• Grant date: Jun 18, 2024
• Expiry date: Oct 20, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.